Coeptis Therapeutics, Inc. (COEP) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Coeptis Therapeutics, Inc. (COEP) Healthcare & Pipeline Overview

Coeptis Therapeutics, Inc. is a biopharmaceutical company specializing in the development of cell therapy platforms and pharmaceutical products for cancer treatment. Their focus on CD38-related cancers, including multiple myeloma, positions them within the competitive biotechnology sector, leveraging collaborations for expanded therapeutic applications.

What Is the Investment Thesis for COEP?

Coeptis Therapeutics presents a high-risk, high-reward investment profile typical of early-stage biopharmaceutical companies. The company's focus on innovative cell therapy platforms, particularly CD38-GEAR-NK, offers potential for significant returns if clinical trials are successful. However, the company's negative profit margin of -611.1% and gross margin of -207.8% highlight the financial challenges inherent in drug development. Key value drivers include the successful advancement of CD38-GEAR-NK through clinical trials and the potential commercialization of CD38-Diagnostic. Collaborations with Statera BioPharma and Vici Health Sciences could also unlock additional value. Investors should closely monitor clinical trial results, regulatory milestones, and the company's ability to secure funding to sustain operations. The negative beta of -0.43 suggests a potential hedge during market downturns, but this should be weighed against the company's inherent volatility.

Based on FMP financials and quantitative analysis

COEP Key Highlights

Market Cap of $38.6M reflects Coeptis Therapeutics' small size and early stage of development within the biotechnology sector.

• Profit Margin of -611.1% indicates significant losses, common for biopharmaceutical companies investing heavily in research and development.
• Gross Margin of -207.8% suggests that the cost of goods or services exceeds revenue, highlighting the need for successful product commercialization.
• Beta of -0.43 indicates that the stock price is negatively correlated with the market, potentially offering some downside protection during market declines.
• No Dividend Yield reflects the company's focus on reinvesting earnings into research and development rather than returning capital to shareholders.

Who Are COEP's Competitors?

COEP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are COEP's Key Strengths?

Innovative cell therapy platforms.

• Focus on CD38-related cancers.
• Strategic collaborations with other companies.
• Development of companion diagnostics for personalized medicine.

What Are COEP's Weaknesses?

Limited financial resources.

• Early stage of development with no approved products.
• High dependence on clinical trial success.
• Small number of employees.

What Could Drive COEP Stock Higher?

Clinical trial results for CD38-GEAR-NK in multiple myeloma (expected Q4 2026).

• Regulatory submission for CD38-Diagnostic (expected Q2 2027).
• Progress in the development of STAT-201 for Crohn's disease in collaboration with Statera BioPharma.
• Advancement of CPT60621 for Parkinson's Disease in partnership with Vici Health Sciences, LLC.

What Are the Key Risks for COEP?

Clinical trial failures for CD38-GEAR-NK or other pipeline candidates.

• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies with greater resources.
• Dependence on securing additional funding to sustain operations.
• Patent infringement or challenges to intellectual property rights.

What Are the Growth Opportunities for COEP?

• CD38-GEAR-NK Development: The primary growth opportunity lies in the successful development and commercialization of CD38-GEAR-NK for CD38-related cancers. Positive clinical trial results and regulatory approval could drive significant revenue growth for Coeptis. The timeline for this opportunity depends on the speed and success of clinical trials, with potential for initial market entry within the next 3-5 years.
• CD38-Diagnostic Commercialization: The commercialization of CD38-Diagnostic as an in vitro screening tool represents another key growth opportunity. By identifying patients most likely to benefit from anti-CD38 therapies, this diagnostic tool could improve treatment outcomes and reduce healthcare costs. The market for companion diagnostics is expanding rapidly, driven by the trend towards personalized medicine. Coeptis could potentially launch CD38-Diagnostic within the next 2-3 years, pending regulatory approval and commercial partnerships.
• STAT-201 for Crohn's Disease: The collaboration with Statera BioPharma to develop STAT-201 for Crohn's disease offers diversification and growth potential beyond oncology. The market for Crohn's disease therapies is substantial, with a growing demand for novel treatments. Successful clinical development and commercialization of STAT-201 could provide Coeptis with a new revenue stream and expand its therapeutic focus. Clinical trials are ongoing, with potential for market entry within the next 4-6 years.
• CPT60621 for Parkinson's Disease: The co-development of CPT60621 with Vici Health Sciences for Parkinson's Disease provides another avenue for growth. The market for Parkinson's disease treatments is expanding due to the aging population. If CPT60621 proves effective in clinical trials, it could generate significant revenue for Coeptis. The timeline for this opportunity is dependent on clinical trial progress, with potential for market entry in 5-7 years.
• Strategic Partnerships and Acquisitions: Coeptis can pursue strategic partnerships and acquisitions to expand its product pipeline and market reach. Collaborating with other biotechnology companies or acquiring promising drug candidates could accelerate growth and diversify risk. This strategy could involve licensing agreements, joint ventures, or outright acquisitions, depending on the specific opportunities that arise. The timeline for this growth opportunity is variable, depending on the availability of suitable targets.

What Threats Does COEP Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles and clinical trial failures.
• Patent expiration and generic competition.
• Economic downturn affecting healthcare spending.

What Are COEP's Competitive Advantages?

• Proprietary cell therapy platforms offer a technological advantage.
• Patent protection on key drug candidates and diagnostic tools.
• Strategic collaborations with established pharmaceutical companies.
• Focus on personalized medicine through diagnostic screening.

What Does COEP Do?

Founded in 2017 and headquartered in Wexford, Pennsylvania, Coeptis Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer patients. The company's core focus lies in cell therapy platforms and pharmaceutical products designed to address unmet needs in oncology. Coeptis's lead product candidate is CD38-GEAR-NK, a Vy-Gen drug product targeting CD38-related cancers such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. This therapy aims to leverage the body's immune system to fight cancer cells. In addition to CD38-GEAR-NK, Coeptis is developing CD38-Diagnostic, an in vitro screening tool designed to predict which cancer patients are most likely to benefit from anti-CD38 monoclonal antibody therapies. This diagnostic tool has the potential to personalize cancer treatment by identifying patients who will respond favorably to specific therapies. Coeptis also engages in strategic collaborations to expand its therapeutic pipeline. The company is collaborating with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease, diversifying its focus beyond oncology. Furthermore, Coeptis has partnered with Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease, indicating an interest in addressing neurological disorders as well. These collaborations are crucial for Coeptis, allowing them to leverage external expertise and resources to advance their product development efforts.

What Products and Services Does COEP Offer?

• Develops cell therapy platforms for cancer treatment.
• Commercializes generic and branded pharmaceutical products.
• Focuses on therapies for CD38-related cancers, including multiple myeloma.
• Develops in vitro screening tools to predict patient response to therapies.
• Collaborates with other companies to expand its therapeutic pipeline.
• Targets unmet needs in oncology and neurological disorders.

How Does COEP Make Money?

• Develops and patents novel therapeutic technologies.
• Conducts clinical trials to evaluate the safety and efficacy of its products.
• Seeks regulatory approval from agencies like the FDA.
• Commercializes approved products through direct sales or partnerships.
• Generates revenue through product sales, licensing agreements, and collaborations.

What Industry Does COEP Operate In?

Coeptis Therapeutics operates in the highly competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and significant financial risks. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like Coeptis face competition from established pharmaceutical giants and other emerging biotech firms. Success in this industry requires strong scientific expertise, effective clinical trial execution, and strategic partnerships to navigate the complex regulatory and commercial landscape. The industry is also subject to evolving market trends, including the rise of personalized medicine and the increasing importance of biomarkers in drug development.

Who Are COEP's Key Customers?

• Cancer patients suffering from CD38-related malignancies.
• Healthcare providers and oncologists prescribing cancer therapies.
• Hospitals and clinics administering cell therapy treatments.
• Pharmaceutical companies seeking to license or acquire novel therapies.

Return on assets is -65.1%, showing how much profit it generates from its asset base. COEP trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

Coeptis Therapeutics, Inc. (COEP) Valuation Context

Valued at $38.6M, COEP is classified as a micro-cap stock.

Company Profile

Coeptis Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Wexford, US. The company is led by CEO David Mehalick. COEP has traded publicly since 2020.

Coeptis Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 10.90 places it in the safe zone, indicating low near-term bankruptcy risk.

Wall Street analysts project Coeptis Therapeutics, Inc. revenue of about $1.0M for fiscal 2026, with EPS near $-3.40.

COEP Financials

COEP Latest News

No recent news available for COEP.

What Investors Ask About Coeptis Therapeutics, Inc. (COEP) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources